The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, according to a new analysis.

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

A doctor from the University of Palermo in Italy has published a case study of an adult cocaine user who experienced reduced ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

Jacobs Solutions CEO Bob Pragada joins 'Squawk Box' to discuss the building opportunities of life science facilities to meet ...

As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...